CXCL10 and thyroid gland papillary carcinoma: Evidence from both papillary thyroid carcinoma and triple-negative breast cancer suggests that elevated CXCL10 expression consistently correlates with improved prognosis, likely reflecting its role in promoting antitumor immune responses across distinct tumor types (42, 43).